Relmada Therapeutics, Inc. - חוב לטווח קצר של החברה RLMD

Relmada Therapeutics (RLMD) enjoys the trust of psychiatry experts due to its scientific potential. The current amount of short-term liabilities on the GURU.Markets terminal produces a chart where the value 0.00 captures the metric level. This is critical as the company integrates innovative NMDA blockers into depression therapy, while the management, possessing the necessary expertise, successfully manages the binary risks of clinical trials.

To minimize risks in long-term investing, it is essential to evaluate the balance between borrowed funds and liquidity, where financial debts with a maturity of up to one year reflect the current capital burden and the business's ability to service its obligations. For Relmada Therapeutics (RLMD), which funds the development of neuropsychiatric drugs from its own reserves, the absence of short-term loans confirms a cash burn strategy without the use of leverage, thereby strengthening the company's financial stability.